Presentation is loading. Please wait.

Presentation is loading. Please wait.

Consortium québécois sur la découverte du médicament Facilitating creative partnerships in biopharmaceutical research Ottawa, November 30 th, 2009 Diane.

Similar presentations


Presentation on theme: "Consortium québécois sur la découverte du médicament Facilitating creative partnerships in biopharmaceutical research Ottawa, November 30 th, 2009 Diane."— Presentation transcript:

1 Consortium québécois sur la découverte du médicament Facilitating creative partnerships in biopharmaceutical research Ottawa, November 30 th, 2009 Diane Gosselin, VP Research and Business Development

2 Consortium québécois sur la découverte du médicament The current pharma R&D business model is increasingly unsatisfactory… … and requires to rethink its operational mode and improve productivity 65.2 billion invested in R&D in 2008 Poor innovative product pipelines Increasing regulatory hurdles Disillusion from expectations of rapid translation from genes to drugs A fostered co-creation of value between academic centers, biotech companies and the pharmaceutical industry The possibility to finance creative pre-competitive research with the potential to impact the whole life science sector A more flexible management of IP processes A better way to channel public funds on research agendas responding to Industry and Regulators needs

3 Consortium québécois sur la découverte du médicament Our mission To identify, finance and support innovative research activities, primarily focusing on enabling technologies in drug discovery, fulfilling the innovation needs of the pharmaceutical industry To create a collaborative ground between the academic and private sectors based on trust, creativity and mutual benefit

4 Consortium québécois sur la découverte du médicament Founding Partners

5 Consortium québécois sur la découverte du médicament A fully mutualized consortium unlike other existing initiatives

6 Consortium québécois sur la découverte du médicament Scope of the funding program Promote the development of innovative enabling technologies that can facilitate biopharmaceutical research Not intended to fund the development of specific molecules Must address the most important challenges of the bio- pharmaceutical industry Must generate clear deliverables with immediate applications in the drug discovery or development process Promote creativity and collaborations between public and private organizations (strongly encouraged, but not mandatory)

7 Consortium québécois sur la découverte du médicament Funding specifics Amount and Duration $1,000,000 - $3,000,000/project (3 years) Subject to milestone achievement and satisfactory follow-ups 3-5 projects funded per year Mentorship For each project a specific industrial advisory committee ensures that the end- products are well aligned with the needs of the biopharmaceutical research industry Intellectual property IP belongs to the inventors and their respective institutions A non exclusive end-user license option will be granted to the CQDMs industrial sponsors for internal research purposes only The owners of IP will maintain the right to exploit or to out-license to third parties

8 Consortium québécois sur la découverte du médicament competition 12 full applications 78 letters of intent 4 selected projects 3 funded projects A total of $6.0M in funding Over 70 researchers from 4 universities and 3 private organizations A total of $6.0M in funding Over 70 researchers from 4 universities and 3 private organizations

9 Consortium québécois sur la découverte du médicament 1.Identification of biomarkers for measurement of pancreatic beta cell mass, function and stratification of treatment response patients. Principal investigator Eustache Paramithiotis, Caprion Proteomics. Budget : $2.305M 2.Development of new vaccine antigens based on Virus-Like Particles (VLPs). Principal investigator: Louis-Philippe Vézina, Medicago. Budget: $1.775M 3.Multiparametric profiling of G protein-coupled receptor efficacy ligand using multiplexed biosensors: linking signalling signatures to therapeutic efficacy. Principal investigator: Michel Bouvier, Unviersity of Montreal. Budget : $1.827 M funded projects

10 Consortium québécois sur la découverte du médicament 1 ) Innovative technology platforms 2) Translational technologies 3) Cutting edge drug delivery technologies Research agenda ( ) This year, priority will be given to the following enabling technologies:

11 Consortium québécois sur la découverte du médicament An innovative consortium Benefits to Pharma companies Access to innovation aligned with the needs of the industry Excellent leverage (>10 fold) for R&D investment dollars Closer links with the academic and the Biotech sectors Cooperative interactions with competitors Closer interactions with government bodies Benefits to Biotech companies and to academic institutions Additional source of funding Access to specialized and dedicated resources Closer links with industrial colleagues Increased international competiveness

12 Consortium québécois sur la découverte du médicament Corporate development CQDM is planning to extend its activities through national and international collaborations CQDM wishes to enter into bilateral agreements with similar organizations in the US and in Europe to finance joint research projects in drug discovery and development Aligning international research resources with global pharma R&D agendas is likely to impact the productivity of drug discovery in the industry


Download ppt "Consortium québécois sur la découverte du médicament Facilitating creative partnerships in biopharmaceutical research Ottawa, November 30 th, 2009 Diane."

Similar presentations


Ads by Google